Novo Aripuana

Researchers are studying felzartamab in adults who have received a kidney transplant and later developed microvascular inflammation MVI, a condition causing injury to small blood vessels in the transplanted kidney. Some cases of MVI occur without antibodies and are called isolated MVI, for which there are currently no approved treatments. This research aims to understand how felzartamab affects inflammation in the transplanted kidney and related health aspects. Participants are randomly assigned to receive either felzartamab or a placebo for 24 weeks without knowing which they receive. After this, all participants receive felzartamab openly for another 28 weeks. Treatments are given through intravenous IV infusions at the study site. Kidney biopsies are done at the start, week 24, and week 52 to observe changes in inflammation. Throughout the study, participants will have lab tests and health monitoring, including recording any health problems that may happen. Researchers will measure kidney inflammation, function, immune activity, and overall health over about one year. Safety is closely watched using biopsies, lab results, and adverse event reports to better understand felzartamabs effects.